GLP-1 Microdosing and Psoriasis: Plaques, Psoriatic Arthritis, and What the Early Studies Show

Consider a 48-year-old electrician with plaque psoriasis on his elbows, knees, and scalp since his twenties. He has gained about 20 kg over the last decade. His dermatologist has noticed that each time his weight climbs, his plaques spread and his topical creams seem to work less well. Now his heels ache when he gets out of bed. He has read online that weight-loss injections clear psoriasis, and he wants to know whether that is true.

The honest answer is "partly, for some people, and not yet at microdose levels." This article covers why excess weight worsens psoriasis, what diet trials showed when people lost weight, what the GLP-1 studies have found so far, and why psoriatic arthritis deserves its own attention. The electrician is a composite example, not a real patient.

Why does excess weight make psoriasis worse?

Excess body fat makes psoriasis worse because fat tissue is itself a source of inflammation. Visceral fat releases TNF-alpha, IL-6, and leptin, and those signals amplify the IL-23 and IL-17 pathway that drives skin cells to overgrow into plaques. Many of the most effective psoriasis drugs, from adalimumab to secukinumab to risankizumab, work by blocking exactly those signals.

The link shows up clearly in population data. A 2012 meta-analysis in Nutrition & Diabetes pooled 16 observational studies and found people with psoriasis had 1.66 times the odds of obesity compared with people without it. The odds rose with severity, from 1.46 in mild disease to 2.23 in severe disease. Weight also affects treatment: ustekinumab is dosed at 90 mg instead of 45 mg above 100 kg, and several studies have linked higher BMI with weaker responses to TNF inhibitors.

Does losing weight without a GLP-1 improve psoriasis?

Losing weight through diet improves psoriasis modestly, and the benefit is clearer for quality of life than for plaque scores alone. In a Danish trial led by Peter Jensen and published in JAMA Dermatology in 2013, 60 people with psoriasis and obesity followed either an 800 to 1,000 calorie diet for 16 weeks or their usual healthy eating. The diet group lost 15.4 kg more than the control group.

That large weight loss moved the Psoriasis Area and Severity Index, or PASI, by only 2 points more than control, a trend that did not reach statistical significance. Baseline PASI was low, at a median of 5.4, which left little room to improve. The Dermatology Life Quality Index, or DLQI, did improve significantly, by 2 points.

A larger Italian trial gave a clearer picture. Luigi Naldi and colleagues randomized 303 overweight or obese people who were already on systemic psoriasis treatment to a 20-week diet and exercise program or to simple advice. The British Journal of Dermatology reported in 2014 that median PASI fell by 48 percent with diet and exercise and by 25.5 percent with advice alone. The point is that weight loss seems to work best as an add-on that helps existing treatment do its job.

What have GLP-1 studies in psoriasis actually found?

GLP-1 studies in psoriasis have mostly found improvement, but nearly all of them are small, short, or uncontrolled. The story began with case reports around 2010 and 2011 of people with type 2 diabetes whose psoriasis improved after starting exenatide or liraglutide. Small open-label studies of liraglutide in China and Europe followed, several reporting falls in PASI over 8 to 12 weeks.

The best-controlled early test was less encouraging. A Danish double-blind trial led by Annesofie Faurschou, published in the Journal of the European Academy of Dermatology and Venereology in 2015, gave liraglutide or placebo to 20 people with psoriasis and obesity but normal glucose tolerance for 8 weeks. PASI did not change significantly between groups. Eight weeks is short and 20 people is few, so the trial was underpowered rather than conclusive.

Semaglutide data arrived in 2025. In an open-label randomized study published in Biomolecules, 31 people with psoriasis and type 2 diabetes either added semaglutide or continued standard care. Median PASI in the semaglutide group fell from 21 to 10 over 12 weeks. A separate study presented at the European Congress on Obesity in 2025 followed 41 people with psoriasis and obesity for three months on semaglutide, and mean PASI fell from 11.3 to 5.5, with lower waist size and CRP.

Could GLP-1 drugs calm psoriasis directly, apart from weight loss?

GLP-1 drugs may calm psoriasis through a direct immune effect, though the human evidence is thin. In 2011, Andrew Hogan and colleagues in Dublin reported in Diabetologia that invariant natural killer T cells, a type of immune cell found in higher numbers in psoriatic plaques, carry the GLP-1 receptor. Liraglutide reduced the inflammatory signals those cells released, and in two patients the plaques improved within weeks, before much weight had been lost.

Mouse studies using the imiquimod model of psoriasis have since shown lower IL-17 and IL-23 levels and thinner skin lesions after GLP-1 drug treatment. In people, the effect of weight loss and the effect on immune cells are hard to separate, since both happen at once. CRP, a general blood marker of inflammation, falls on GLP-1 drugs in most trials. Our article on GLP-1 and inflammation covers that broader picture, and our piece on skin health and collagen looks at other skin effects.

What about psoriatic arthritis?

Psoriatic arthritis appears to respond to weight loss more strongly than skin plaques do. Roughly one in four to one in three people with psoriasis develop psoriatic arthritis, which causes joint pain, swollen fingers or toes, and heel or lower back pain. Excess weight adds mechanical load to those joints and fuels the same inflammatory signals.

In a 2014 study in the Annals of the Rheumatic Diseases, Matteo Di Minno and colleagues followed 138 overweight or obese people with psoriatic arthritis who were starting a TNF inhibitor alongside a diet program. At six months, the share reaching minimal disease activity rose steadily with the amount of weight lost. A Swedish study led by Eva Klingberg in 2019 found that a very low energy diet producing about 18 percent weight loss improved joint, skin, and enthesitis scores in people with psoriatic arthritis and obesity.

The electrician's aching heels could be a sign of enthesitis, inflammation where tendons attach to bone, which is common in psoriatic arthritis. That symptom calls for a rheumatology assessment regardless of any weight plan. Our article on joint health and osteoarthritis covers the mechanical side of joint load.

Does any of this apply to a GLP-1 microdose?

None of the psoriasis findings has been tested at microdose levels. The semaglutide studies escalated toward standard weekly doses, and the diet trials that worked best produced 10 percent or more weight loss. A microdose usually produces smaller and slower weight change, so a full-dose result cannot simply be scaled down.

Two open questions make the microdose angle interesting rather than dismissible. If part of the benefit comes from a direct effect on immune cells, that effect might show up at lower doses than the weight effect does. And because physical stress from vomiting or dehydration can trigger flares, a gentler dose may be easier to stay on. Both ideas are hypotheses. Our microdosing guide explains typical dose ranges, and our article on managing nausea covers tolerability.

What should people with psoriasis watch for on a GLP-1?

People with psoriasis on a GLP-1 should track their skin with dated photos, keep their existing psoriasis treatment unchanged unless the dermatologist says otherwise, and watch for joint symptoms. Psoriasis waxes and wanes with season, stress, and infection, so a single good month proves little. Photos taken in the same light every four weeks give a far more honest record than memory.

Psoriasis also carries higher rates of fatty liver, high blood pressure, and heart disease, especially when methotrexate or certain other drugs are part of treatment. Liver enzymes, lipids, and blood sugar are worth checking at baseline. Our articles on liver health and biomarkers to track go further. This table helps sort common situations:

What is the takeaway?

The takeaway is that weight loss helps psoriasis and especially psoriatic arthritis in people who carry excess weight, and early semaglutide studies point the same way. The GLP-1 evidence is still small, short, and mostly unblinded, and a direct immune effect remains a hypothesis in humans. For the electrician, the useful steps are a rheumatology check for his heels, a talk with his dermatologist about weight as part of his plan, and no change to treatment that already works.

Frequently asked questions

Clinical references

1. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutrition & Diabetes. 2012;2(12):e54.
2. Jensen P, Zachariae C, Christensen R, et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatology. 2013;149(7):795-801.
3. Naldi L, Conti A, Cazzaniga S, et al. Diet and physical exercise in psoriasis: a randomized controlled trial. British Journal of Dermatology. 2014;170(3):634-642.
4. Di Minno MND, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Annals of the Rheumatic Diseases. 2014;73(6):1157-1162.
5. Klingberg E, Bilberg A, Björkman S, et al. Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. Arthritis Research & Therapy. 2019;21(1):17.
6. Faurschou A, Gyldenløve M, Rohde U, et al. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients: a randomized placebo-controlled trial. Journal of the European Academy of Dermatology and Venereology. 2015;29(3):555-559.
7. Hogan AE, Tobin AM, Ahern T, et al. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia. 2011;54(11):2745-2754.
8. Petković-Dabić J, Binić I, Carić B, et al. Effects of semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label, randomized clinical trial. Biomolecules. 2025;15(1):46.
9. Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. Journal of the American Academy of Dermatology. 2019;80(4):1073-1113.